752.88 USD
-3.08 (-0.41%)
752.88 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to IDXX. IDXX was compared to 188 industry peers in the Health Care Equipment & Supplies industry. IDXX gets an excellent profitability rating and is at the same time showing great financial health properties. IDXX has a correct valuation and a medium growth rate. With these ratings, IDXX could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
IDXX had positive earnings in the past year.
IDXX had a positive operating cash flow in the past year.
Each year in the past 5 years IDXX has been profitable.
IDXX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
IDXX's Return On Assets of 30.34% is amongst the best of the industry. IDXX outperforms 99.47% of its industry peers.
IDXX has a better Return On Equity (65.81%) than 99.47% of its industry peers.
Looking at the Return On Invested Capital, with a value of 40.25%, IDXX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for IDXX is significantly above the industry average of 8.71%.
The last Return On Invested Capital (40.25%) for IDXX is above the 3 year average (35.08%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROIC | 40.25% |
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
1.3 Margins
IDXX has a better Profit Margin (24.65%) than 94.68% of its industry peers.
IDXX's Profit Margin has improved in the last couple of years.
IDXX's Operating Margin of 31.34% is amongst the best of the industry. IDXX outperforms 98.40% of its industry peers.
In the last couple of years the Operating Margin of IDXX has grown nicely.
IDXX has a better Gross Margin (61.72%) than 61.70% of its industry peers.
IDXX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% |
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IDXX is creating value.
Compared to 1 year ago, IDXX has less shares outstanding
Compared to 5 years ago, IDXX has less shares outstanding
The debt/assets ratio for IDXX has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 24.88 indicates that IDXX is not in any danger for bankruptcy at the moment.
The Altman-Z score of IDXX (24.88) is better than 96.81% of its industry peers.
The Debt to FCF ratio of IDXX is 1.04, which is an excellent value as it means it would take IDXX, only 1.04 years of fcf income to pay off all of its debts.
IDXX has a Debt to FCF ratio of 1.04. This is amongst the best in the industry. IDXX outperforms 90.96% of its industry peers.
A Debt/Equity ratio of 0.53 indicates that IDXX is somewhat dependend on debt financing.
IDXX has a Debt to Equity ratio (0.53) which is comparable to the rest of the industry.
Although IDXX does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Altman-Z | 24.88 |
ROIC/WACC4.49
WACC8.97%
2.3 Liquidity
IDXX has a Current Ratio of 1.18. This is a normal value and indicates that IDXX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.18, IDXX is doing worse than 83.51% of the companies in the same industry.
IDXX has a Quick Ratio of 1.18. This is a bad value and indicates that IDXX is not financially healthy enough and could expect problems in meeting its short term obligations.
IDXX's Quick ratio of 0.87 is on the low side compared to the rest of the industry. IDXX is outperformed by 82.98% of its industry peers.
The current and quick ratio evaluation for IDXX is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
IDXX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.16%, which is quite good.
Measured over the past years, IDXX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 18.18% on average per year.
The Revenue has grown by 8.39% in the past year. This is quite good.
The Revenue has been growing by 10.12% on average over the past years. This is quite good.
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%
3.2 Future
IDXX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.81% yearly.
The Revenue is expected to grow by 9.18% on average over the next years. This is quite good.
EPS Next Y14.37%
EPS Next 2Y13.33%
EPS Next 3Y13.16%
EPS Next 5Y13.81%
Revenue Next Year9.1%
Revenue Next 2Y8.66%
Revenue Next 3Y8.63%
Revenue Next 5Y9.18%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
IDXX is valuated quite expensively with a Price/Earnings ratio of 59.70.
Based on the Price/Earnings ratio, IDXX is valued a bit cheaper than the industry average as 68.09% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of IDXX to the average of the S&P500 Index (26.31), we can say IDXX is valued expensively.
Based on the Price/Forward Earnings ratio of 52.11, the valuation of IDXX can be described as expensive.
Based on the Price/Forward Earnings ratio, IDXX is valued a bit cheaper than the industry average as 69.15% of the companies are valued more expensively.
IDXX is valuated rather expensively when we compare the Price/Forward Earnings ratio to 36.59, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.7 | ||
| Fwd PE | 52.11 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 68.62% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, IDXX is valued a bit cheaper than the industry average as 71.81% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 63.94 | ||
| EV/EBITDA | 41.79 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IDXX does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of IDXX may justify a higher PE ratio.
A more expensive valuation may be justified as IDXX's earnings are expected to grow with 13.16% in the coming years.
PEG (NY)4.16
PEG (5Y)3.28
EPS Next 2Y13.33%
EPS Next 3Y13.16%
5. Dividend
5.1 Amount
IDXX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
752.88
-3.08 (-0.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners97.04%
Inst Owner Change-0.97%
Ins Owners0.2%
Ins Owner Change2.58%
Market Cap60.12B
Revenue(TTM)4.17B
Net Income(TTM)1.03B
Analysts80
Price Target773.18 (2.7%)
Short Float %2.16%
Short Ratio3.63
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)11.33%
PT rev (3m)11.82%
EPS NQ rev (1m)1.27%
EPS NQ rev (3m)1.8%
EPS NY rev (1m)0%
EPS NY rev (3m)0.09%
Revenue NQ rev (1m)1.39%
Revenue NQ rev (3m)1.48%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.7 | ||
| Fwd PE | 52.11 | ||
| P/S | 14.43 | ||
| P/FCF | 63.94 | ||
| P/OCF | 55.25 | ||
| P/B | 38.51 | ||
| P/tB | 58.21 | ||
| EV/EBITDA | 41.79 |
EPS(TTM)12.61
EY1.67%
EPS(NY)14.45
Fwd EY1.92%
FCF(TTM)11.77
FCFY1.56%
OCF(TTM)13.63
OCFY1.81%
SpS52.19
BVpS19.55
TBVpS12.93
PEG (NY)4.16
PEG (5Y)3.28
Graham Number74.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROCE | 61.18% | ||
| ROIC | 40.25% | ||
| ROICexc | 43.77% | ||
| ROICexgc | 56.25% | ||
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% | ||
| FCFM | 22.56% |
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
ROICexc(3y)39.8%
ROICexc(5y)41.54%
ROICexgc(3y)51.52%
ROICexgc(5y)54.7%
ROCE(3y)52.73%
ROCE(5y)50.92%
ROICexgc growth 3Y-5.99%
ROICexgc growth 5Y4.28%
ROICexc growth 3Y-3.86%
ROICexc growth 5Y4.07%
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 105.48% | ||
| Cap/Sales | 3.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 75.23% | ||
| Profit Quality | 91.51% | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 24.88 |
F-Score8
WACC8.97%
ROIC/WACC4.49
Cap/Depr(3y)119.67%
Cap/Depr(5y)117.13%
Cap/Sales(3y)3.91%
Cap/Sales(5y)3.89%
Profit Quality(3y)79.31%
Profit Quality(5y)83.23%
High Growth Momentum
Growth
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
EPS Next Y14.37%
EPS Next 2Y13.33%
EPS Next 3Y13.16%
EPS Next 5Y13.81%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%
Revenue Next Year9.1%
Revenue Next 2Y8.66%
Revenue Next 3Y8.63%
Revenue Next 5Y9.18%
EBIT growth 1Y17.46%
EBIT growth 3Y6.64%
EBIT growth 5Y15.38%
EBIT Next Year31.91%
EBIT Next 3Y16.8%
EBIT Next 5Y14.77%
FCF growth 1Y38.31%
FCF growth 3Y7.86%
FCF growth 5Y21.3%
OCF growth 1Y31.08%
OCF growth 3Y7.13%
OCF growth 5Y15.14%
IDEXX LABORATORIES INC / IDXX FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to IDXX.
Can you provide the valuation status for IDEXX LABORATORIES INC?
ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.
Can you provide the profitability details for IDEXX LABORATORIES INC?
IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.
What is the valuation of IDEXX LABORATORIES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 59.7 and the Price/Book (PB) ratio is 38.51.
Can you provide the expected EPS growth for IDXX stock?
The Earnings per Share (EPS) of IDEXX LABORATORIES INC (IDXX) is expected to grow by 14.37% in the next year.